Acasti Pharma Inc. Investor Presentation Now Available Online

Editor's Note: There is a photo and a video associated with this release.

On October 24, 2011 The Howard Group hosted its 3rd annual "Opportunity Knocks"
investor conference in Calgary. Tina Sampalis, President of Acasti (TSX
VENTURE:APO) provided an overview of the company to an audience of investment
advisors & private investors. 


A recording of the presentation is now available online. Click here to view -
http://www.howardgroupinc.com/Portals/0/Acasti/presentation_vid/index.html


Highlights on Acasti are as follows:



--  Founded 2008 - Listed 03/2011 (TSX VENTURE:APO) 
    Subsidiary of Neptune Technologies 
--  NKO Krill based Omega-3 Phospholipid products focused on natural
    cholesterol management. Decreases Triglycerides; Decreases LDL (bad
    cholesterol); Increases HDL (good cholesterol); Potential enhancer of
    Statin therapy; Potential use in Statin intolerant patients. 
--  Full access to Neptune's manufacturing & intellectual property. 
--  Very recently, Neptune & Acasti were granted an important patent, which
    is key for both companies in relation to the U.S. market. 
--  LAST WEEK Doug Loe at Byron Capital Markets gave this company a BUY
    rating with a $3.50 target price. 



About Acasti Pharma Inc. 

Acasti Pharma is developing a product portfolio of proprietary novel long-chain
omega-3 phospholipids. Phospholipids are the major component of cell membranes
and are essential for all vital cell processes. They are one of the principal
constituents of High Density Lipoprotein (good cholesterol) and, as such, play
an important role in modulating cholesterol efflux. Acasti Pharma's proprietary
novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty
acids EPA and DHA, which have been shown to have substantial health benefits and
which are stabilized by potent antioxidants. Acasti Pharma is focusing initially
on treatments for chronic cardiovascular and cardiometabolic conditions within
the over-the-counter, medical food and prescription drug markets. 


About Neptune Technologies & Bioressources Inc. 

Neptune is an industry-recognized leader in the innovation, production and
formulation of science-based and clinically proven novel phospholipid products
for the nutraceutical and pharmaceutical markets. The Company focuses on growing
consumer health markets including cardiovascular, inflammatory and neurological
diseases driven by consumers taking a more proactive approach to managing health
and preventing disease. The Company sponsors clinical trials aimed to
demonstrate its product health benefits and to obtain regulatory approval for
label health claims. Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals. Neptune's
products are marketed and distributed in over 20 countries worldwide.


Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results of
the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.


To view the fact sheet associated with this release, please see the following
link: http://media3.marketwire.com/docs/Acasti_Factsheet.pdf


To view the photo associated with this release, please see the following link:
http://www.marketwire.com/library/20111110-Acasti800.jpg